Jazz Pharmaceuticals (JAZZ) reported adjusted earnings of $2.68 per share in first-quarter 2024, missing the Zacks Consensus Estimate of$4.14. Earnings fell 32% year over year, primarily due to increased operating expenses incurred during the quarter. Total revenues in the reported quarter rose 1% year over year to $902 million, driven by higher oncology product sales, which were partially offset by lower neuroscience revenues. Per management, revenues were impacted by seasonal headwinds from payor reautho ...